|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1638.70
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 17,410.50 | 3,068.60 | 8,555.70 | 32,530.00 | 7,194.50 | Adjustment | 48,234.00 | 12,662.90 | 17,178.70 | -2,170.90 | 4,486.60 | Changes In working Capital | -56,253.80 | 39,036.70 | -27,522.80 | -13,930.00 | 1,115.00 | Cash Flow after changes in Working Capital | 9,390.70 | 54,768.20 | -1,788.40 | 16,429.10 | 12,796.10 | Cash Flow from Operating Activities | 5,070.80 | 76,363.60 | -4,165.10 | 13,058.50 | 12,421.80 | Cash Flow from Investing Activities | -7,051.70 | -27,021.00 | 14,638.10 | 14,792.90 | 4,336.90 | Cash Flow from Financing Activities | 1,693.10 | -48,708.50 | -9,997.30 | -28,711.50 | -14,685.90 | Net Cash Inflow / Outflow | -287.80 | 634.10 | 475.70 | -860.10 | 2,072.80 | Opening Cash & Cash Equivalents | 4,195.30 | 3,510.60 | 3,148.30 | 3,027.60 | 978.00 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 195.30 | 50.60 | -113.40 | 37.50 | -23.20 | Closing Cash & Cash Equivalent | 4,102.80 | 4,195.30 | 3,510.60 | 2,205.00 | 3,027.60 |
|
|
|
|
|
|